TY - JOUR
T1 - A framework for interpreting genome-wide association studies of psychiatric disorders
AU - The Psychiatric GWAS Consortium Steering Committee
AU - Cichon, Sven
AU - Craddock, Nick
AU - Daly, Mark
AU - Faraone, Stephen V.
AU - Gejman, Pablo V.
AU - Kelsoe, John
AU - Lehner, Thomas
AU - Levinson, Douglas F.
AU - Moran, Audra
AU - Sklar, Pamela
AU - Sullivan, Patrick F.
N1 - Funding Information:
This article was written early in the history of the PGC by its coordinating committee who takes responsibility for its content. We wish to acknowledge our enduring debt to our PGC colleagues for their many contributions to this work. The members of the PGC Coordinating Committee are: Sven Cichon (University of Bonn), Nick Craddock (Cardiff University), Mark Daly (Harvard Medical School, Broad Institute), Stephen V Faraone (SUNY Upstate Medical University), Pablo V Gejman (Evanston Northwestern Healthcare and Feinberg School of Medicine, North-western University), John Kelsoe (University of California, San Diego), Thomas Lehner (NIMH), Douglas F Levinson (Stanford University), Audra Moran (NARSAD, ex officio), Pamela Sklar (Massachusetts General Hospital, Broad Institute) and Patrick F Sullivan (University of North Carolina at Chapel Hill). The PGC is supported by NIMH MH085520 (http://www.nimh.gov). Statistical analyses are conducted on the Genetic Cluster Computer, which is supported by the Netherlands Scientific Organization (NWO 480-05-003, PI Danielle Posthuma) along with a supplement from the Dutch Brain Foundation (http://www.hersenstichting.nl, PI Roel Ophoff). We are indebted to NARSAD for infrastructure support.
PY - 2009/1/25
Y1 - 2009/1/25
N2 - Genome-wide association studies (GWAS) have yielded a plethora of new findings in the past 3 years. By early 2009, GWAS on 47 samples of subjects with attention-deficit hyperactivity disorder, autism, bipolar disorder, major depressive disorder and schizophrenia will be completed. Taken together, these GWAS constitute the largest biological experiment ever conducted in psychiatry (59 000 independent cases and controls, 7700 family trios and >40 billion genotypes). We know that GWAS can work, and the question now is whether it will work for psychiatric disorders. In this review, we describe these studies, the Psychiatric GWAS Consortium for meta-analyses of these data, and provide a logical framework for interpretation of some of the conceivable outcomes.
AB - Genome-wide association studies (GWAS) have yielded a plethora of new findings in the past 3 years. By early 2009, GWAS on 47 samples of subjects with attention-deficit hyperactivity disorder, autism, bipolar disorder, major depressive disorder and schizophrenia will be completed. Taken together, these GWAS constitute the largest biological experiment ever conducted in psychiatry (59 000 independent cases and controls, 7700 family trios and >40 billion genotypes). We know that GWAS can work, and the question now is whether it will work for psychiatric disorders. In this review, we describe these studies, the Psychiatric GWAS Consortium for meta-analyses of these data, and provide a logical framework for interpretation of some of the conceivable outcomes.
KW - Attention-deficit hyperactivity disorder
KW - Autism
KW - Bipolar disorder
KW - Genome-wide association
KW - Major depressive disorder
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=58049194158&partnerID=8YFLogxK
U2 - 10.1038/mp.2008.126
DO - 10.1038/mp.2008.126
M3 - Review article
AN - SCOPUS:58049194158
SN - 1359-4184
VL - 14
SP - 10
EP - 17
JO - Molecular Psychiatry
JF - Molecular Psychiatry
IS - 1
ER -